ArticleCurrent neuropharmacology2011
Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.
Article in Current neuropharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Role of memantine in adult migraine: a systematic review and network meta-analysis to compare memantine with existing migraine preventive medications.Frontiers in pharmacology · 2024Pooled it
- Citalopram Neuroendocrine Challenge Shows Altered Tryptophan and Kynurenine Metabolism in Migraine.Cells · 2022Trial
- The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects.International journal of molecular sciences · 2024Review
- Alkoxyalkylation of Electron-Rich Aromatic Compounds.International journal of molecular sciences · 2024Review
- Article
- Article
- Ion Channel Disturbances in Migraine Headache: Exploring the Potential Role of the Kynurenine System in the Context of the Trigeminovascular System.International journal of molecular sciences · 2023Review
- The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Novel Eco-friendly, One-Pot Method for the Synthesis of Kynurenic Acid Ethyl Esters.ACS omega · 2023Article
- Organic anion transporter 1 is an HDAC4-regulated mediator of nociceptive hypersensitivity in mice.Nature communications · 2022Article
- Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research.Biomedicines · 2021Review
- The Organ of Vision and the Stomatognathic System-Review of Association Studies and Evidence-Based Discussion.Brain sciences · 2021Review
- Effect of 4-week physical exercises on tryptophan, kynurenine and kynurenic acid content in human sweat.Scientific reports · 2021Article
- Article
- Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model.Frontiers in pharmacology · 2018Article
- Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.Internal and emergency medicine · 2015Review
- Kynurenines and other novel therapeutic strategies in the treatment of dementia.Therapeutic advances in neurological disorders · 2013Article
- Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability.Drug design, development and therapy · 2013Article
- Kynurenines in the CNS: recent advances and new questions.Nature reviews. Drug discovery · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is one of the commonest neurological disorders. Despite intensive research, its exact pathomechanism is still not fully understood and effective therapy is not always available. One of the key molecules involved in migraine is glutamate, whose receptors are found on the first-, second- and third-order trigeminal neurones and are also present in the migraine generators, including the dorsal raphe nucleus, nucleus raphe magnus, locus coeruleus and periaqueductal grey matter. Glutamate receptors are important in cortical spreading depression, which may be the electrophysiological correlate of migraine aura. The kynurenine metabolites, endogenous tryptophan metabolites, include kynurenic acid (KYNA), which exerts a blocking effect on ionotropic glutamate and α7-nicotinic acetylcholine receptors. Thus, KYNA and its derivatives may act as modulators at various levels of the pathomechanism of migraine. They can give rise to antinociceptive effects at the periphery, in the trigeminal nucleus caudalis, and may also act on migraine generators and cortical spreading depression. The experimental data suggest that KYNA or its derivatives might offer a novel approach to migraine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.